Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
14.9M
-
Shares change
-
+20.2K
-
Total reported value, excl. options
-
$17M
-
Value change
-
+$181K
-
Put/Call ratio
-
0.02
-
Number of buys
-
14
-
Number of sells
-
-14
-
Price
-
$1.14
Significant Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q1 2023
43 filings reported holding AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q1 2023.
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.9M shares
of 120M outstanding shares and own 12.43% of the company stock.
Largest 10 shareholders include Bratton Capital Management, L.P. (9.81M shares), VANGUARD GROUP INC (1.31M shares), Vahanian & Associates Financial Planning Inc. (719K shares), RENAISSANCE TECHNOLOGIES LLC (519K shares), Bracebridge Capital, LLC (429K shares), GEODE CAPITAL MANAGEMENT, LLC (388K shares), BlackRock Inc. (360K shares), MILLENNIUM MANAGEMENT LLC (303K shares), Latash Investments, LLC (243K shares), and BRIDGEWAY CAPITAL MANAGEMENT, LLC (143K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.